Will this new pill mess with your cholesterol meds?

NCT ID NCT07534592

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial in 48 healthy volunteers checks whether a new drug called elecoglipron changes how the body processes two common statins (atorvastatin and rosuvastatin). Participants take the statin alone and later with elecoglipron, and researchers measure drug levels in the blood. The goal is to see if there is a drug interaction, which could guide safe use in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elecoglipron
What this could lead to: If successful, this study could help doctors understand whether elecoglipron can be safely taken with common cholesterol-lowering statins.
What could go wrong: This is an early Phase 1 trial in only 48 healthy people, so results may not apply to patients or predict real-world safety. The study focuses on drug levels, not treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Research Site

Glendale, California, 91206, United States
Research Site

Brooklyn, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.